SCHEMBL3099137

SCHEMBL3099137

CC(Oc1ccc2nc(-c3ccc(OC(N)=O)cc3)sc2c1)c1c(Cl)cccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.45
NR1H4 Q96RI1 1/20 0.43
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
FGFR1 P11362 1/20 0.42
THRB P10828 1/20 0.42
SULT1A1 P50225 1/20 0.42
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
MET P08581 1/20 0.41
KDR P35968 1/20 0.41
RORC P51449 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104841 0.91 MET (0.46) APPMAPTSMN1; SMN2THRBSULT1A1
SCHEMBL3104758 0.88 APP (0.47) APPMAPTSULT1A1KDM4ENPC1
SCHEMBL3108713 0.88 MET (0.56) APPMETKDR
SCHEMBL3099179 0.87 MAPT (0.43) APPNR1H4MAPTSMN1; SMN2THRB
SCHEMBL3102687 0.87 MAPT (0.40) APPNR1H4MAPTSMN1; SMN2FGFR1
SCHEMBL3093478 0.86 APP (0.41) APPNR1H4MAPTSMN1; SMN2THRB
SCHEMBL3104161 0.86 MET (0.47) APPMAPTSMN1; SMN2THRBSULT1A1
SCHEMBL3093441 0.86 MET (0.45) APPMAPTSMN1; SMN2THRBSULT1A1
SCHEMBL3099130 0.85 DYRK1A (0.43) NR1H4MAPTSMN1; SMN2FGFR1NPC1
SCHEMBL3109563 0.85 APP (0.46) APPMAPTSMN1; SMN2THRBSULT1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 APP 4658/4885NR1H4 710/4885MAPT 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.